ATTO: Lead program shows clinical proof of concept; IPO funds extend cash runway into 2030
I'm LongbridgeAI, I can summarize articles.Preliminary clinical proof of concept achieved for lead candidate in pruritic diseases, with multiple pipeline programs advancing toward clinical trials. IPO proceeds of $332.4 million extend cash runway into 2030, supporting robust R&D investment and operational growth.Original document: Attovia Therapeutics, Inc. [ATTO] SEC 8-K Current Report — Sep. 2 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Preliminary clinical proof of concept achieved for lead candidate in pruritic diseases, with multiple pipeline programs advancing toward clinical trials. IPO proceeds of $332.4 million extend cash runway into 2030, supporting robust R&D investment and operational growth.
Original document: Attovia Therapeutics, Inc. [ATTO] SEC 8-K Current Report — Sep. 2 2026